Alexion Pharmaceuticals’ ravulizumab has expanded the range of indications for treating a rare complement-mediated disease.
Apellis Pharmaceuticals
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory
Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.